The DOI matches its Crossref record.
Molecular genetics of muccpolysaccharidosis type I: Diagnostic, clinical, and biological implications
Abstract
Mucopolysaccharidosis type I (MPS-I) is an autosomal recessive disease caused by mutations in the alpha-L-iduronidase (IDUA) gene. These mutations lead to a deficiency of the glycosidase alpha-L-iduronidase (IDUA), which is required for the degradation of heparan sulphate and dermatan sulphate and thus the storage of these glycosaminoglycans in the lysosome. There is a wide range of clinical phenotypes in MPS-I (eponyms: Hurler syndrome, severe; Hurler/Scheie syndrome, intermediate; Scheie syndrome, mild), which makes prediction of disease severity and genetic counselling difficult. However, since cloning of the IDUA gene, mutation analysis has provided some molecular explanations for the range of MPS-I phenotypes, in turn facilitating the selection and evaluation of patients undergoing experimental treatment protocols such as bone marrow transplantation. A total of 46 mutations now have been defined for MPS-I consisting of 8 nonsense mutations, 21 missense mutations, 3 splice site mutations, and 14 minor deletions and/or insertions. Furthermore, 30 polymorphisms or nonpathogenic sequence variants have been defined, including 7 amino acid substitutions. Among patients of European origin, there are two major MPS-I mutations and a number of less frequent mutations. It is possible to follow mutation analysis of 292 patients, which can be divided into eight main patient groups of different ethnic and/or geographic origin with significant variation in mutant allele frequencies. A complex picture of molecular heterogeneity is emerging, building a valuable database for genotype/phenotype correlation. Mutation analysis is also providing some of the first clues into the structure and function of IDUA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Enzyme-Replacement Therapy in Mucopolysaccharidosis I
Kakkis, E. D., Muenzer, J., Tiller, G. E., Waber, L., Belmont, J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101183440304 · Cited by 667
Overview of the mucopolysaccharidoses
Muenzer, J. (2011) · Rheumatology · doi:10.1093/rheumatology/ker394 · Cited by 486
Mucopolysaccharidosis I: Management and Treatment Guidelines
Muenzer, J., Wraith, J. E., Clarke, L. A., & and the International Consensus Panel on the Management and Treatment of Mucopolysaccharidosis, I. (2009) · Pediatrics · doi:10.1542/peds.2008-0416 · Cited by 460
Self-citationRegulation of lysosomal ion homeostasis by channels and transporters
Xiong, J., & Zhu, M. X. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5090-x · Cited by 141
“…2000) beta-Glucuronidase/GUSB 3.5 mucopolysaccharidosis type VII (Shipley et al., 1993) alpha-L-iduronidase/IDUA 3.5 mucopolysaccharidosis type I (Scott et al., 1995) Napsin A 3.5 – (Aguilera et al., 2003) Cathepsin D 3.5 – (Barrett, 1977) Cathepsin X/Z/P 3.5 – (Nägler et al.,…”
InfluentialBelur, L. R., Temme, A., Podetz-Pedersen, K. M., Riedl, M., Vulchanova, L., Robinson, N., Hanson, L. R., Kozarsky, K. F., Orchard, P. J., Frey, W. H., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.187 · Cited by 67
Metadata
- Authors
- Scott, H. S., Bunge, S., Gal, A., Clarke, L. A., Morris, C. P., & Hopwood, J. J.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 1995
- Volume
- 6
- Issue
- 4
- Pages
- 288-302
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W1993553242
- Cited by
- 204
- References
- 0
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular genetics of muccpolysaccharidosis type I: Diagnostic, clinical, and biological implications. https://app.cochat.ai/papers/10.1002/humu.1380060403
- The paper
- Scott, H. S., Bunge, S., Gal, A., Clarke, L. A., Morris, C. P., & Hopwood, J. J. (1995). Molecular genetics of muccpolysaccharidosis type I: Diagnostic, clinical, and biological implications. Human Mutation. https://doi.org/10.1002/humu.1380060403
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.